See every side of every news story
Published loading...Updated

AstraZeneca may quit London stock market

GREATER LONDON, ENGLAND, JUL 1 – AstraZeneca CEO cites UK regulatory hurdles and tax concerns amid plans to move listing to US, where over 40% of the company's $54 billion revenue is generated.

  • AstraZeneca's chief executive Sir Pascal Soriot is reportedly considering shifting the company's stock market listing from London to the US as of July 2025.
  • This consideration follows years of frustration with the UK's tax regime, NHS drug rebate scheme, and regulatory barriers hindering new medicine approvals.
  • AstraZeneca has already invested more heavily in the US and China, including a $2.5 billion investment and plans for a new R&D center in Beijing.
  • Soriot stated, “Companies will follow where they feel welcome,” highlighting that investment flows to favorable markets, while AstraZeneca's shares fell 17% in the past year before a 2.8% rise.
  • Such a decision would significantly damage the London Stock Exchange and pose a serious threat to the UK's life sciences industry, heightening worries about the nation's ability to remain competitive.
Insights by Ground AI
Does this summary seem wrong?

28 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 47% of the sources are Center
47% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Axios broke the news in Washington, United States on Tuesday, July 1, 2025.
Sources are mostly out of (0)